Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC-CIK and CIK with Chemotherapy for Advanced Solid Tumors
NCT03047525Phase 2Unknown
- Start
- Feb 2017
- Primary completion
- Jan 2019
- Modality
- Whole Cell Cancer Vaccines, Allogeneic CAR-T, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dendritic cell vaccine + cytokine-induced killer cells and unmodified CIK in colorectal cancer (CRC), renal cell carcinoma (RCC), nasopharyngeal carcinoma (NPC) and 1 more (2 arms). Primary endpoint: Progression-Free Survival at 1 month. Status: unknown.
02
Drugs
dendritic cell vaccine + cytokine-induced killer cellsunmodified CIK
03
Conditions
colorectal cancer (CRC)renal cell carcinoma (RCC)nasopharyngeal carcinoma (NPC)lung cancer
Beyond the preview
Go deeper on NCT03047525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03047525.